Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be292b122d407a915b90a727e32fd9a25> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be292b122d407a915b90a727e32fd9a25 NCIT_P378 "NCI" @default.
- Be292b122d407a915b90a727e32fd9a25 type Axiom @default.
- Be292b122d407a915b90a727e32fd9a25 annotatedProperty IAO_0000115 @default.
- Be292b122d407a915b90a727e32fd9a25 annotatedSource NCIT_C78865 @default.
- Be292b122d407a915b90a727e32fd9a25 annotatedTarget "An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21." @default.